PFS in treatment subgroups by first-line therapy in the ASCT-intent subgroup
| . | Denosumab . | Zoledronic acid . |
|---|---|---|
| Patients who received triplet therapy (VRd, CVd, CTd, or VTd) | ||
| No. of patients* | 354 | 347 |
| Patients with a PFS event, n (%) | 65 (18.4) | 92 (26.5) |
| Median PFS (95% CI), mo | NE (NE-NE) | 35.7 (30.2-NE) |
| HR† (95% CI) | 0.65 (0.47-0.90) | |
| Descriptive P value | .009 | |
| Patients who received bortezomib-only (no IMiD) therapy (CVd or Vd) | ||
| No. of patients‡ | 186 | 214 |
| Patients with a PFS event, n (%) | 34 (18.3) | 59 (27.6) |
| Median PFS (95% CI), mo | NE (38.7-NE) | NE (30.2-NE) |
| HR† (95% CI) | 0.61 (0.39-0.95) | |
| Descriptive P value | .029 | |
| Patients who received doublet therapy (Rd, Td, or Vd) | ||
| No. of patients* | 67 | 87 |
| Patients with PFS event, n (%) | 16 (23.9) | 30 (34.5) |
| Median PFS (95% CI), mo | NE (25.1-NE) | 36.7 (22.2-NE) |
| HR† (95% CI) | 0.83 (0.40-1.74) | |
| Descriptive P value | .62 | |
| Patients who received VRd | ||
| No. of patients* | 80 | 61 |
| Patients with a PFS event, n (%) | 18 (22.5) | 12 (19.7) |
| Median PFS (95% CI), mo | NE (30.2-NE) | 35.7 (19.4-NE) |
| HR† (95% CI) | 1.20 (0.53-2.75) | |
| Descriptive P value | .66 | |
| Patients who received IMiD-only therapy (Rd or Td) | ||
| No. of patients* | 20 | 33 |
| Patients with a PFS event, n (%) | 5 (25.0) | 11 (33.3) |
| Median PFS (95% CI), mo | NE (18.4-NE) | 34.3 (22.3-NE) |
| HR† (95% CI) | 1.82 (0.18–18.25) | |
| Descriptive P value | .61 | |
| . | Denosumab . | Zoledronic acid . |
|---|---|---|
| Patients who received triplet therapy (VRd, CVd, CTd, or VTd) | ||
| No. of patients* | 354 | 347 |
| Patients with a PFS event, n (%) | 65 (18.4) | 92 (26.5) |
| Median PFS (95% CI), mo | NE (NE-NE) | 35.7 (30.2-NE) |
| HR† (95% CI) | 0.65 (0.47-0.90) | |
| Descriptive P value | .009 | |
| Patients who received bortezomib-only (no IMiD) therapy (CVd or Vd) | ||
| No. of patients‡ | 186 | 214 |
| Patients with a PFS event, n (%) | 34 (18.3) | 59 (27.6) |
| Median PFS (95% CI), mo | NE (38.7-NE) | NE (30.2-NE) |
| HR† (95% CI) | 0.61 (0.39-0.95) | |
| Descriptive P value | .029 | |
| Patients who received doublet therapy (Rd, Td, or Vd) | ||
| No. of patients* | 67 | 87 |
| Patients with PFS event, n (%) | 16 (23.9) | 30 (34.5) |
| Median PFS (95% CI), mo | NE (25.1-NE) | 36.7 (22.2-NE) |
| HR† (95% CI) | 0.83 (0.40-1.74) | |
| Descriptive P value | .62 | |
| Patients who received VRd | ||
| No. of patients* | 80 | 61 |
| Patients with a PFS event, n (%) | 18 (22.5) | 12 (19.7) |
| Median PFS (95% CI), mo | NE (30.2-NE) | 35.7 (19.4-NE) |
| HR† (95% CI) | 1.20 (0.53-2.75) | |
| Descriptive P value | .66 | |
| Patients who received IMiD-only therapy (Rd or Td) | ||
| No. of patients* | 20 | 33 |
| Patients with a PFS event, n (%) | 5 (25.0) | 11 (33.3) |
| Median PFS (95% CI), mo | NE (18.4-NE) | 34.3 (22.3-NE) |
| HR† (95% CI) | 1.82 (0.18–18.25) | |
| Descriptive P value | .61 | |
Numbers were based on the ranked therapies in a descending order of efficacy: VRd>VTd>CVd>CTd>Vd>Rd>Td; a patient was counted only 1 time in the highest ranking therapy group received.
HR <1 favors denosumab.
Number of patients who received CVd or Vd but did not receive any other triplet or doublet therapies.